Shares of Mankind Pharma will be in focus on Wednesday, May 22, after the company reported its Q4 FY25 results post market hours on Tuesday.
The pharmaceutical major posted a 27.1% year-on-year rise in revenue, which stood at ₹3,079.4 crore for the January–March quarter, up from ₹2,422.2 crore in the same period last year. The growth was driven by robust performance in both domestic formulations and exports.
However, profitability metrics showed a decline, with EBITDA margin contracting to 22.2% from 24.2% a year earlier, indicating cost pressures or changes in product mix.
Ahead of the results, shares of Mankind Pharma closed 0.75% lower at ₹2,530.00 on May 21. The stock opened at ₹2,532.10 and touched a low of ₹2,516.10 during the session. It had settled at ₹2,549.20 in the previous close.
The market will track the stock’s reaction to this mixed performance when trading resumes today.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a financial advisor before making any investment decisions.
